These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
465 related articles for article (PubMed ID: 25645208)
1. β-Lactam combinations with daptomycin provide synergy against vancomycin-resistant Enterococcus faecalis and Enterococcus faecium. Smith JR; Barber KE; Raut A; Aboutaleb M; Sakoulas G; Rybak MJ J Antimicrob Chemother; 2015; 70(6):1738-43. PubMed ID: 25645208 [TBL] [Abstract][Full Text] [Related]
2. β-Lactams enhance daptomycin activity against vancomycin-resistant Enterococcus faecalis and Enterococcus faecium in in vitro pharmacokinetic/pharmacodynamic models. Smith JR; Barber KE; Raut A; Rybak MJ Antimicrob Agents Chemother; 2015 May; 59(5):2842-8. PubMed ID: 25753639 [TBL] [Abstract][Full Text] [Related]
3. Oritavancin Combinations with β-Lactams against Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci. Smith JR; Yim J; Raut A; Rybak MJ Antimicrob Agents Chemother; 2016 Apr; 60(4):2352-8. PubMed ID: 26833159 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of the novel combination of daptomycin plus ceftriaxone against vancomycin-resistant enterococci in an in vitro pharmacokinetic/pharmacodynamic simulated endocardial vegetation model. Hall Snyder A; Werth BJ; Barber KE; Sakoulas G; Rybak MJ J Antimicrob Chemother; 2014 Aug; 69(8):2148-54. PubMed ID: 24777900 [TBL] [Abstract][Full Text] [Related]
5. Impact of Daptomycin Dose Exposure Alone or in Combination with β-Lactams or Rifampin against Vancomycin-Resistant Enterococci in an Jahanbakhsh S; Singh NB; Yim J; Kebriaei R; Smith JR; Lev K; Tran TT; Rose WE; Arias CA; Rybak MJ Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32094136 [No Abstract] [Full Text] [Related]
6. In vitro activity of daptomycin in combination with β-lactams, gentamicin, rifampin, and tigecycline against daptomycin-nonsusceptible enterococci. Hindler JA; Wong-Beringer A; Charlton CL; Miller SA; Kelesidis T; Carvalho M; Sakoulas G; Nonejuie P; Pogliano J; Nizet V; Humphries R Antimicrob Agents Chemother; 2015 Jul; 59(7):4279-88. PubMed ID: 25963982 [TBL] [Abstract][Full Text] [Related]
7. 1,2,4-Oxadiazole antimicrobials act synergistically with daptomycin and display rapid kill kinetics against MDR Enterococcus faecium. Carter GP; Harjani JR; Li L; Pitcher NP; Nong Y; Riley TV; Williamson DA; Stinear TP; Baell JB; Howden BP J Antimicrob Chemother; 2018 Jun; 73(6):1562-1569. PubMed ID: 29518208 [TBL] [Abstract][Full Text] [Related]
8. Ampicillin enhances daptomycin- and cationic host defense peptide-mediated killing of ampicillin- and vancomycin-resistant Enterococcus faecium. Sakoulas G; Bayer AS; Pogliano J; Tsuji BT; Yang SJ; Mishra NN; Nizet V; Yeaman MR; Moise PA Antimicrob Agents Chemother; 2012 Feb; 56(2):838-44. PubMed ID: 22123698 [TBL] [Abstract][Full Text] [Related]
9. Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium. McKay GA; Beaulieu S; Arhin FF; Belley A; Sarmiento I; Parr T; Moeck G J Antimicrob Chemother; 2009 Jun; 63(6):1191-9. PubMed ID: 19369269 [TBL] [Abstract][Full Text] [Related]
12. Early in vitro development of daptomycin non-susceptibility in high-level aminoglycoside-resistant Enterococcus faecalis predicts the efficacy of the combination of high-dose daptomycin plus ampicillin in an in vivo model of experimental endocarditis. Pericàs JM; García-de-la-Mària C; Brunet M; Armero Y; García-González J; Casals G; Almela M; Quintana E; Falces C; Ninot S; Fuster D; Llopis J; Marco F; Moreno A; Miró JM; J Antimicrob Chemother; 2017 Jun; 72(6):1714-1722. PubMed ID: 28204495 [TBL] [Abstract][Full Text] [Related]
13. Mechanistic Insights Into the Differential Efficacy of Daptomycin Plus β-Lactam Combinations Against Daptomycin-Resistant Enterococcus faecium. Kebriaei R; Stamper KC; Singh KV; Khan A; Rice SA; Dinh AQ; Tran TT; Murray BE; Arias CA; Rybak MJ J Infect Dis; 2020 Oct; 222(9):1531-1539. PubMed ID: 32514561 [TBL] [Abstract][Full Text] [Related]
14. Phage-Antibiotic Cocktail Rescues Daptomycin and Phage Susceptibility against Daptomycin-Nonsusceptible Enterococcus faecium in a Simulated Endocardial Vegetation Kunz Coyne AJ; Stamper K; El Ghali A; Kebriaei R; Biswas B; Wilson M; Deschenes MV; Tran TT; Arias CA; Rybak MJ Microbiol Spectr; 2023 Aug; 11(4):e0034023. PubMed ID: 37338375 [TBL] [Abstract][Full Text] [Related]
15. Efficacy of daptomycin in the treatment of experimental endocarditis due to susceptible and multidrug-resistant enterococci. Vouillamoz J; Moreillon P; Giddey M; Entenza JM J Antimicrob Chemother; 2006 Dec; 58(6):1208-14. PubMed ID: 17030515 [TBL] [Abstract][Full Text] [Related]
16. Biofilm Time-Kill Curves to Assess the Bactericidal Activity of Daptomycin Combinations against Biofilm-Producing Vancomycin-Resistant Barber KE; Shammout Z; Smith JR; Kebriaei R; Morrisette T; Rybak MJ Antibiotics (Basel); 2021 Jul; 10(8):. PubMed ID: 34438947 [TBL] [Abstract][Full Text] [Related]
17. Ceftaroline Plus Ampicillin Against Gram-Positive Organisms: Results from E-Test Synergy Assays. D'Arezzo S; Mazzarelli A; Venditti C; Nisii C; Petrosillo N; De Giuli C; Vulcano A; Paglia MG; Bordi E; Di Caro A; Taglietti F Microb Drug Resist; 2017 Jun; 23(4):507-515. PubMed ID: 27526275 [TBL] [Abstract][Full Text] [Related]
18. In vitro activity of oritavancin alone or in combination against vancomycin-susceptible and -resistant enterococci. Wu T; Meyer K; Harrington AT; Danziger LH; Wenzler E J Antimicrob Chemother; 2019 May; 74(5):1300-1305. PubMed ID: 30753495 [TBL] [Abstract][Full Text] [Related]
19. In vitro activity of ampicillin and ceftriaxone against ampicillin-susceptible Enterococcus faecium. Lorenzo MP; Kidd JM; Jenkins SG; Nicolau DP; Housman ST J Antimicrob Chemother; 2019 Aug; 74(8):2269-2273. PubMed ID: 31050740 [TBL] [Abstract][Full Text] [Related]
20. Antimicrobial susceptibility of daptomycin and comparator agents tested against methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: trend analysis of a 6-year period in US medical centers (2005-2010). Sader HS; Moet GJ; Farrell DJ; Jones RN Diagn Microbiol Infect Dis; 2011 Jul; 70(3):412-6. PubMed ID: 21546202 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]